Home/Pipeline/ACE-2223

ACE-2223

Amyotrophic Lateral Sclerosis (ALS)

PreclinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Preclinical

Status

Active

Company

Acelot

About Acelot

Acelot is a private, preclinical-stage biotech applying a novel AI-driven drug discovery platform to historically intractable protein targets, starting with TDP-43 in ALS. The company's lead candidate, ACE-2223, is designed to inhibit and dissociate toxic TDP-43 aggregates, aiming to restore the protein's healthy function and address the root cause of the disease. With a team combining deep technical and entrepreneurial experience, Acelot is positioning itself as a pioneer in targeting TDP-43 pathology, a common driver across multiple neurodegenerative conditions. The company is actively presenting research and engaging with the scientific and investor community to advance its programs.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Amyotrophic Lateral Sclerosis

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active